A late-stage trial of oral drug named Paxlovid conducted by Pfizer shown a 89% cut of hospitalization and death risk, making them halts their trial due to "overhelmed efficiacy.
A late-stage trial of theoral drug Paxlovid conducted by Pfizer shows an 89% reductioninhospitalizations and deaths.